Imagine a disease so archaic it was once the bane of 17th-century sailors, now making a shocking comeback in the 21st century—all because of a popular weight-loss trend. Yes, scurvy is back, and it’s not just sailors who are at risk. But here’s where it gets controversial: could the very drugs designed to help us shed pounds be silently sabotaging our health? This week, top Australian dietitians are sounding the alarm about an unexpected side effect of GLP-1 medications like Ozempic, Wegovy, and Mounjaro. These drugs, hailed as game-changers for weight loss and diabetes management, are now under scrutiny for potentially leading to malnutrition—and in extreme cases, scurvy. But this is the part most people miss: the issue isn’t just about losing weight; it’s about losing essential nutrients along the way.
In a groundbreaking systematic review led by Professor Clare Collins of the Newcastle School of Health Sciences, researchers uncovered a startling gap in global trials of these drugs. Very few studies have bothered to track what patients are actually eating while on these medications. This oversight, experts warn, has left many users functionally malnourished, with some developing severe vitamin deficiencies. Collins bluntly told the Australian Financial Review, ‘A reduction in body weight does not automatically mean the person is well-nourished or healthy. Nutrition plays a critical role in health, and right now, it’s largely missing from the evidence.’
Take the case of British pop star Robbie Williams, who openly discussed his use of injectable weight-loss medication and later revealed his battle with scurvy—a condition he dubbed a ‘17th-century pirate disease.’ While scurvy, caused by a lack of vitamin C, is rare in developed countries today, its resurgence raises a troubling question: Are we trading one health crisis for another?
Here’s the kicker: Only two out of over 40 studies analyzed by Collins’ team actually measured patients’ diets. ‘This is being missed,’ she said, emphasizing the lack of data on how these drugs impact dietary intake. Without proper oversight, patients risk not just scurvy but other complications like thiamine deficiency, which can lead to neurological and cardiovascular issues. And let’s not forget the recent reports linking GLP-1 drugs to eating disorders and rare cancers.
But before you swear off these medications entirely, consider this: Ozempic and Wegovy still offer significant benefits for many, and ongoing research continues to explore their optimal use. Some longevity experts even suggest microdoses of semaglutide could have anti-aging effects, reducing the risk of heart attacks and strokes. In 2024, the National Institute of Health reported that 12% of U.S. adults had used a GLP-1 drug, with even higher rates among those with diabetes. Clearly, these medications aren’t going anywhere.
So, what’s the solution? Dietitians Australia CEO Magriet Raxworthy stresses the need for personalized medical nutrition therapy for GLP-1 users. Without it, she warns, ‘people may struggle to meet their nutritional needs and can be placed at risk of significant muscle loss, bone density loss, micronutrient deficiencies, and disordered eating behaviors.’ Medication alone, she argues, is not enough for sustainable health.
And this is where the debate heats up: Should GLP-1 drugs come with mandatory dietary counseling? Or is it the responsibility of healthcare providers to ensure patients are educated about their nutritional needs? What do you think? Are these drugs a miracle solution or a ticking time bomb? Share your thoughts in the comments—let’s spark a conversation that could shape the future of weight-loss treatments.
